This article was last updated on 10/01/2023.
Follica is a U.S.-based biotechnology company currently developing a hair loss treatment device. The device, known as the Follica Hair Follicle Neogenesis Device, may see a name change upon its market release.
As of 2023, the device is in phase 3 of testing, indicating that the company has already conducted preliminary safety and efficacy trials with promising results. Indeed, the results from phase 2 have shown positive outcomes, providing hope for individuals dealing with hair loss.
Currently, only one image of the Follica device is available on their website:
(source)
The image on Follica’s website does not provide a clear distinction of how the device sets itself apart from other microneedling devices available in the market. However, as per the information presented on their website, their device utilizes patented technology, giving it specific attributes.
It’s essential to note that treatment sessions using the Follica device must be administered in a clinical setting by a qualified professional. This requirement suggests that the microneedles used in the procedure may be longer than those employed in other treatments, or that the procedure may involve the application of a specific serum.
Here is an illustration shared on their site:
(source)
At the bottom of the illustration, it mentions “Device plus drug.” This implies that Follica must be used in combination with another treatment to achieve its full potential.
A Phase 2 study
A scientific study conducted during the Phase 2 of clinical trials by Follica has shown that the combined use of the Follica device with a topical treatment was effective in treating female androgenetic alopecia.
Eleven women underwent treatment with Follica’s device (Follica Hair Follicle Neogenesis Device) for three months, totaling six sessions, while simultaneously using 5% minoxidil every night.
Here is an image from the study:
(source)
Phase 3 testing start date
In June 2020, Follica issued a press release to announce the initiation of Phase 3 testing. As of the current year, 2023 (the date of my article), we are still awaiting further updates from Follica. It is my hope that we may see some results emerge in the coming year or the next.
I will update this article as soon as I receive new information.